Recursion Pharmaceuticals (NASDAQ: RXRX) didn't have a fine start to the working week on Monday, at least as far as its stock ...

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it ...

Q1 2025 Management View CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, ...

When pigeons outnumber pigeonholes, some birds must double up. This obvious statement, and its inverse, have deep connections ...